Abstract
AnnexinA5 has been found to act as an oncogenic protein in a variety of cancers. However, its specific biological role and mechanism in renal cell cancer(RCC) remains unknown. Quantitative Real-time PCR and western blotting were used to evaluate the mRNA and protein expression level of AnnexinA5 in human RCC cell lines and tissues. Immunohistochemistry was adopted to measure the AnnexinA5 expression in 123cases of RCC tissues. Survival analysis was performed to explore the association between AnnexinA5 expression and the prognosis of RCC. The effect of AnnexinA5 on RCC growth and metastasis was studied invitro and invivo. AnnexinA5 was frequently highly expressed in both human RCC cells and tissues. High AnnexinA5 expression was associated with higher clinical stage and histological grade. In addition, AnnexinA5 might be used as a predictive factor for the prognosis of RCC. Further research suggested that upregulated AnnexinA5 in RCC cells could significantly promote tumor cell proliferation, migration and invasion invitro. Subcutaneous xenograft tumor model displayed that knockdown of AnnexinA5 could impede tumorigenesis invivo. Moreover, mechanism study exhibited that AnnexinA5 could activate PI3K/Akt/mTOR signaling pathway, promote epithelial-mesenchymal transition(EMT) and the expression of MMP2 and MMP9. AnnexinA5 may be a potential prognostic biomarker in RCC and promotes proliferation, migration and invasion of RCC cells via activating PI3K/Akt/mTOR signaling pathway and regulating EMT process and MMP expression.
Highlights
Renal cell carcinoma (RCC) is the most common type of kidney cancer with approximately 62,700 new RCC casesKey words: Annexin A5, renal cell cancer, prognosis, proliferation diagnosed and 14,240 new mortalities in the United States in 2016, accounting for approximately 2-3% of all adult malignancies [1]
To explore the protein and mRNA expression of Annexin A5 in RCC cell lines, western blot and Quantitative real-time PCR (qRT-PCR) were performed in four human RCC cell lines (Caki-1, Caki-2, ACHN and 769P) and one normal epithelial cell of renal tubule (HK2)
To assess whether Annexin A5 was highly expressed in RCC tissues, 22 pairs of RCC tissues and matched adjacent non-cancerous tissue were selected for qRT-PCR and western blot, the results suggested that Annexin A5 expression was markedly upregulated in both protein and mRNA level compared to the adjacent tissue (Fig. 1B-D)
Summary
Renal cell carcinoma (RCC) is the most common type of kidney cancer with approximately 62,700 new RCC cases. Annexins can reversibly bind to negatively charged phospholipids in a Ca2+ regulated manner [5]. The non-glycosylated phospholipid binding protein, Annexin A5 is composed of 319 amino acid residues with a molecular mass of ~35.7 kDa [7,8,9]. It is likely that Annexin A5 has a very short unphosphorylated N-terminus compared with other Annexins, contributing to a series of functions, such as cell proliferation and invasion [6,10], signal transduction [11,12], and anticoagulation [13]. We analyzed the expression level of Annexin A5 in RCC tissue samples compared with normal renal tissue samples and explored its potential biomedical functions on RCC cell invasion to confirm whether Annexin A5 is a new molecular biomarker of RCC
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
